|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2024
Brioli, Annamaria 
ORCID: https://orcid.org/0000-0002-4072-7592; Lomaia, Elza ORCID: https://orcid.org/0000-0003-3290-7961; Fabisch, Christian; Sacha, Tomasz ORCID: https://orcid.org/0000-0002-7207-6595; Klamova, Hana; Morozova, Elena; Golos, Aleksandra; Ernst, Philipp ORCID: https://orcid.org/0000-0001-5165-9874; Olsson-Stromberg, Ulla; Zackova, Daniela; Nicolini, Franck E.; Bao, Han; Castagnetti, Fausto ORCID: https://orcid.org/0000-0002-0602-2628; Patkowska, Elzbieta ORCID: https://orcid.org/0000-0001-8691-4310; Mayer, Jiri; Hirschbühl, Klaus ORCID: https://orcid.org/0000-0002-4847-7460; Podgornik, Helena ORCID: https://orcid.org/0000-0003-3752-2067; Paczkowska, Edyta ORCID: https://orcid.org/0000-0001-7052-9741; Parry, Anne; Ernst, Thomas ORCID: https://orcid.org/0000-0003-2147-489X; Voskanyan, Astghik; Szczepanek, Elzbieta; Saussele, Susanne ORCID: https://orcid.org/0000-0003-0357-5785; Franke, Georg-Nikolaus ORCID: https://orcid.org/0000-0001-8239-002X; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Faber, Edgar; Krause, Stefan ORCID: https://orcid.org/0000-0002-5259-4651; Casado, Luis Felipe; Lewandowski, Krzysztof; Eder, Matthias; Anhut, Peter; Gil, Justyna; Südhoff, Thomas; Hebart, Holger ORCID: https://orcid.org/0000-0003-4536-9955; Heibl, Sonja; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Hochhaus, Andreas und Lauseker, Michael ORCID: https://orcid.org/0000-0002-6662-7127
(2024):
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry.
In: Leukemia [Forthcoming]
ORCID: https://orcid.org/0000-0002-4072-7592; Lomaia, Elza ORCID: https://orcid.org/0000-0003-3290-7961; Fabisch, Christian; Sacha, Tomasz ORCID: https://orcid.org/0000-0002-7207-6595; Klamova, Hana; Morozova, Elena; Golos, Aleksandra; Ernst, Philipp ORCID: https://orcid.org/0000-0001-5165-9874; Olsson-Stromberg, Ulla; Zackova, Daniela; Nicolini, Franck E.; Bao, Han; Castagnetti, Fausto ORCID: https://orcid.org/0000-0002-0602-2628; Patkowska, Elzbieta ORCID: https://orcid.org/0000-0001-8691-4310; Mayer, Jiri; Hirschbühl, Klaus ORCID: https://orcid.org/0000-0002-4847-7460; Podgornik, Helena ORCID: https://orcid.org/0000-0003-3752-2067; Paczkowska, Edyta ORCID: https://orcid.org/0000-0001-7052-9741; Parry, Anne; Ernst, Thomas ORCID: https://orcid.org/0000-0003-2147-489X; Voskanyan, Astghik; Szczepanek, Elzbieta; Saussele, Susanne ORCID: https://orcid.org/0000-0003-0357-5785; Franke, Georg-Nikolaus ORCID: https://orcid.org/0000-0001-8239-002X; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Faber, Edgar; Krause, Stefan ORCID: https://orcid.org/0000-0002-5259-4651; Casado, Luis Felipe; Lewandowski, Krzysztof; Eder, Matthias; Anhut, Peter; Gil, Justyna; Südhoff, Thomas; Hebart, Holger ORCID: https://orcid.org/0000-0003-4536-9955; Heibl, Sonja; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Hochhaus, Andreas und Lauseker, Michael ORCID: https://orcid.org/0000-0002-6662-7127
(2024):
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry.
In: Leukemia [Forthcoming]
2023
Isfort, Susanne ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
2022
Schönfeld, Lioba; Rinke, Jenny; Hinze, Anna; Nagel, Saskia N.; Schäfer, Vivien; Schenk, Thomas; Fabisch, Christian; Brümmendorf, Tim H. ORCID: https://orcid.org/0000-0002-9677-3723; Burchert, Andreas ORCID: https://orcid.org/0000-0002-8411-8844; Coutre, Philipp le; Krause, Stefan W. ORCID: https://orcid.org/0000-0002-5259-4651; Saussele, Susanne ORCID: https://orcid.org/0000-0003-0357-5785; Safizadeh, Fatemeh; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Hochhaus, Andreas ORCID: https://orcid.org/0000-0003-0626-0834 und Ernst, Thomas ORCID: https://orcid.org/0000-0003-2147-489X
(2022):
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
In: Leukemia, Bd. 36: S. 2242-2249
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-9677-3723; Burchert, Andreas ORCID: https://orcid.org/0000-0002-8411-8844; Coutre, Philipp le; Krause, Stefan W. ORCID: https://orcid.org/0000-0002-5259-4651; Saussele, Susanne ORCID: https://orcid.org/0000-0003-0357-5785; Safizadeh, Fatemeh; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Hochhaus, Andreas ORCID: https://orcid.org/0000-0003-0626-0834 und Ernst, Thomas ORCID: https://orcid.org/0000-0003-2147-489X
(2022):
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
In: Leukemia, Bd. 36: S. 2242-2249
[PDF, 1MB]
Hess, Georg; Huettmann, Andreas; Witzens-Harig, Mathias; Dreyling, Martin H.; Keller, Ulrich; Marks, Reinhard; Ernst, Thomas; Pott, Christiane; Viardot, Andreas; Frontzek, Fabian; Trautmann, Marcel; Ruckes, Christian; Deuster, Oliver; Rosenwald, Andreas; Theobald, Matthias und Lenz, Georg
(2022):
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
In: British Journal of Haematology, Bd. 198, Nr. 3: S. 482-491
2020
Herrmann, Andreas B.; Müller, Martha-Lena; Orth, Martin F.; Müller, Jörg P.; Zernecke, Alma; Hochhaus, Andreas; Ernst, Thomas; Butt, Elke und Frietsch, Jochen J.
(2020):
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
In: Journal of Cellular and Molecular Medicine, Bd. 24, Nr. 5: S. 2942-2955
Butt, Elke; Stempfle, Katrin; Lister, Lorenz; Wolf, Felix; Kraft, Marcella; Herrmann, Andreas B.; Viciano, Cristina Perpina; Weber, Christian; Hochhaus, Andreas; Ernst, Thomas; Hoffmann, Carsten; Zernecke, Alma und Frietsch, Jochen J.
(2020):
Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia.
In: Cells, Bd. 9, Nr. 2, 444
2018
Drube, Julia; Ernst, Thomas; Pfirrmann, Markus; Albert, Benadict Vincent; Drube, Sebastian; Reich, Daniela; Kresinsky, Anne; Halfter, Kathrin; Sorio, Claudio; Fabisch, Christian; Hochhaus, Andreas und Böhmer, Frank-D
(2018):
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
In: Oncotarget, Bd. 9, Nr. 10: S. 9442-9455